The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Integrins as therapeutic targets: lessons and opportunities
Open accessAbstract
The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and autoimmune disorders, has revealed their substantial potential as therapeutic targets. However, so far, pharmacological inhibitors for only three integrins have received marketing approval. This article discusses the structure and function of integrins, their roles in disease and the chequered history of the approved integrin antagonists. Recent advances in the understanding of integrin function, ligand interaction and signalling pathways suggest novel strategies for inhibiting integrin function that could help harness their full potential as therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
New Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Xiong, J.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., & Arnaout, M. A. (2002) · Science · doi:10.1126/science.1069040 · Cited by 1,613
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Crystal Structure of the Extracellular Segment of Integrin αVβ3
Xiong, J.-P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., & Arnaout, M. A. (2001) · Science · doi:10.1126/science.1064535 · Cited by 1,276
Takagi, J., Petre, B. M., Walz, T., & Springer, T. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00935-2 · Cited by 1,168
The final steps of integrin activation: the end game
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2871 · Cited by 1,086
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
Ramirez, A., Fisher, G., George, E. L., Sanning, E., Forouzani, M., Allen, J., Bak, R., Halley, W., Wheeler, G., her, et al. (2003) · Cited by 960
Investigators, T. R. (1997) · Circulation · doi:10.1161/01.cir.96.5.1445 · Cited by 945
Tamkun, J. W., DeSimone, D. W., Fonda, D., Patel, R. S., Buck, C., Horwitz, A. F., & Hynes, R. O. (1986) · Cell · doi:10.1016/0092-8674(86)90744-0 · Cited by 871
Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics
Xiao, T., Takagi, J., Coller, B. S., Wang, J.-H., & Springer, T. A. (2004) · Nature · doi:10.1038/nature02976 · Cited by 846
Bidirectional Transmembrane Signaling by Cytoplasmic Domain Separation in Integrins
Kim, M., Carman, C. V., & Springer, T. A. (2003) · Science · doi:10.1126/science.1084174 · Cited by 786
Tan, C. S., & Koralnik, I. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70040-5 · Cited by 776
The Tail of Integrins, Talin, and Kindlins
Moser, M., Legate, K. R., Zent, R., & Fässler, R. (2009) · Science · doi:10.1126/science.1163865 · Cited by 760
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Structural Basis of Integrin Activation by Talin
Wegener, K. L., Partridge, A. W., Han, J., Pickford, A. R., Liddington, R. C., Ginsberg, M. H., & Campbell, I. D. (2007) · Cell · doi:10.1016/j.cell.2006.10.048 · Cited by 676
Integrin cytoplasmic domains mediate inside-out signal transduction
O'Toole, T., Katagiri, Y., Faull, R., Peter, K., Tamura, R., Quaranta, V, Loftus, J., Shattil, S., & Ginsberg, M. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.6.1047 · Cited by 661
Kim, S., Bell, K., Mousa, S. A., & Varner, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65005-5 · Cited by 635
Helicobacter exploits integrin for type IV secretion and kinase activation
Kwok, T., Zabler, D., Urman, S., Rohde, M., Hartig, R., Wessler, S., Misselwitz, R., Berger, J., Sewald, N., König, W., et al. (2007) · Nature · doi:10.1038/nature06187 · Cited by 619
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
LICHTMAN, M., SPIVAK, J., BOXER, L., SHATTIL, S., & HENDERSON, E. (2000) · Hematology · doi:10.1016/b978-012448510-5/50164-3 · Cited by 605
Drug-Induced Immune Thrombocytopenia
Aster, R. H., & Bougie, D. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066469 · Cited by 578
Integrins: roles in cancer development and as treatment targets
Jin, H., & Varner, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601576 · Cited by 574
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030002 · Cited by 570
INTEGRIN STRUCTURE, ALLOSTERY, AND BIDIRECTIONAL SIGNALING
Arnaout, M. A., Mahalingam, B., & Xiong, J.-P. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.090704.151217 · Cited by 550
Vinogradova, O., Velyvis, A., Velyviene, A., Hu, B., Haas, T. A., Plow, E. F., & Qin, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00906-6 · Cited by 530
Shimaoka, M., Xiao, T., Liu, J.-H., Yang, Y., Dong, Y., Jun, C.-D., McCormack, A., Zhang, R., Joachimiak, A., Takagi, J., et al. (2003) · Cell · doi:10.1016/s0092-8674(02)01257-6 · Cited by 516
Pytela, R., Pierschbacher, M. D., & Ruoslahti, E. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.17.5766 · Cited by 511
Reynolds, A. R., Hart, I. R., Watson, A. R., Welti, J. C., Silva, R. G., Robinson, S. D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M. C., et al. (2009) · Nature Medicine · doi:10.1038/nm.1941 · Cited by 490
The interaction of bacterial pathogens with platelets
Fitzgerald, J. R., Foster, T. J., & Cox, D. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1425 · Cited by 489
Self-citationReardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 481
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C. H., O'Connor, P. W., Giovannoni, G., Phillips, J. T., Lublin, F. D., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70021-3 · Cited by 471
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Hughes, P. E., & Pfaff, M. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01339-7 · Cited by 435
Calderwood, D. A., Fujioka, Y., de Pereda, J. M., García-Alvarez, B., Nakamoto, T., Margolis, B., McGlade, C. J., Liddington, R. C., & Ginsberg, M. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262791999 · Cited by 427
Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial
Gordon, K. B., Papp, K. A., Hamilton, T. K., Walicke, P. A., Dummer, W., Li, N., Bresnahan, B. W., Menter, A., & for the Efalizumab Study Group (2003) · JAMA · doi:10.1001/jama.290.23.3073 · Cited by 391
Mechanisms that regulate adaptor binding to β-integrin cytoplasmic tails
Legate, K. R., & Fässler, R. (2009) · Journal of Cell Science · doi:10.1242/jcs.041624 · Cited by 370
Chew, D. P., Bhatt, D. L., Sapp, S., & Topol, E. J. (2001) · Circulation · doi:10.1161/01.cir.103.2.201 · Cited by 359
Coller, B. S., & Shattil, S. J. (2008) · Blood · doi:10.1182/blood-2008-06-077891 · Cited by 352
Therapeutic antagonists and conformational regulation of integrin function
Shimaoka, M., & Springer, T. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1174 · Cited by 349
Implantation mechanisms: insights from the sheep
Spencer, T. E., Johnson, G. A., Bazer, F. W., & Burghardt, R. C. (2004) · Reproduction · doi:10.1530/rep.1.00398 · Cited by 344
Integrin-linked kinase – essential roles in physiology and cancer biology
McDonald, P. C., Fielding, A. B., & Dedhar, S. (2008) · Journal of Cell Science · doi:10.1242/jcs.017996 · Cited by 344
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL
Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta, S. L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., O'Connor, P. W., Phillips, J. T., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000277457.17420.b5 · Cited by 339
Binding of paxillin to α4 integrins modifies integrin-dependent biological responses
Liu, S., Thomas, S. M., Woodside, D. G., Rose, D. M., Kiosses, W. B., Pfaff, M., & Ginsberg, M. H. (1999) · Nature · doi:10.1038/45264 · Cited by 329
Linking integrin conformation to function
Askari, J. A., Buckley, P. A., Mould, A. P., & Humphries, M. J. (2009) · Journal of Cell Science · doi:10.1242/jcs.018556 · Cited by 321
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
Steinman, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1752 · Cited by 317
Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale
Rice, G. P. A., Hartung, H.-P., & Calabresi, P. A. (2005) · Neurology · doi:10.1212/01.wnl.0000158329.30470.d0 · Cited by 305
Harburger, D. S., Bouaouina, M., & Calderwood, D. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809233200 · Cited by 304
Computational Design of Peptides That Target Transmembrane Helices
Yin, H., Slusky, J. S., Berger, B. W., Walters, R. S., Vilaire, G., Litvinov, R. I., Lear, J. D., Caputo, G. A., Bennett, J. S., & DeGrado, W. F. (2007) · Science · doi:10.1126/science.1136782 · Cited by 289
Evans, R., Patzak, I., Svensson, L., De Filippo, K., Jones, K., McDowall, A., & Hogg, N. (2009) · Journal of Cell Science · doi:10.1242/jcs.019117 · Cited by 281
Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland, B., Cohen, P. S., Hui, A.-M., Palmieri, C., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.049452 · Cited by 280
Naik, U. P., Patel, P. M., & Parise, L. V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.8.4651 · Cited by 259
Kallen, J., Welzenbach, K., Ramage, P., Geyl, D., Kriwacki, R., Legge, G., Cottens, S., Weitz-Schmidt, G., & Hommel, U. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3047 · Cited by 256
Integrins: The Keys to Unlocking Angiogenesis
Silva, R., D'Amico, G., Hodivala-Dilke, K. M., & Reynolds, L. E. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.172015 · Cited by 255
Cell integrins: commonly used receptors for diverse viral pathogens
Stewart, P. L., & Nemerow, G. R. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.10.001 · Cited by 230
Disruption of thetalin gene arrests mouse development at the gastrulation stage
Monkley, S. J., Zhou, X.-H., Kinston, S., Giblett, S. M., Hemmings, L., Priddle, H., Brown, J., Pritchard, C. A., Critchley, D. R., & F�ssler, R. (2000) · Developmental Dynamics · doi:10.1002/1097-0177(2000)9999:9999<::aid-dvdy1079>3.0.co;2-y · Cited by 221
Kim, S., Harris, M., & Varner, J. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003668200 · Cited by 216
Kent, S. J., Karlik, S. J., Cannon, C., Hines, D. K., Yednock, T. A., Fritz, L. C., & Horner, H. C. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00165-k · Cited by 201
Fitzgerald, J. R., Loughman, A., Keane, F., Brennan, M., Knobel, M., Higgins, J., Visai, L., Speziale, P., Cox, D., & Foster, T. J. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04922.x · Cited by 194
Self-citationSalas, A., Shimaoka, M., Kogan, A. N., Harwood, C., von Andrian, U. H., & Springer, T. A. (2004) · Immunity · doi:10.1016/s1074-7613(04)00082-2 · Cited by 193
Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., et al. (2010) · Cancer · doi:10.1002/cncr.24821 · Cited by 189
(1997) · Experientia Supplementum · doi:10.1007/978-3-0348-9006-9 · Cited by 185
Cianfrocca, M. E., Kimmel, K. A., Gallo, J., Cardoso, T., Brown, M. M., Hudes, G., Lewis, N., Weiner, L., Lam, G. N., Brown, S. C., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603171 · Cited by 184
Structure of an integrin with an αI domain, complement receptor type 4
Xie, C., Zhu, J., Chen, X., Mi, L., Nishida, N., & Springer, T. A. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.367 · Cited by 182
Egbertson, M. S., Chang, C. T.-C., Duggan, M. E., Gould, R. J., Halczenko, W., Hartman, G. D., Laswell, W. L., Lynch, J. J., & Lynch, R. J. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00042a007 · Cited by 180
Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma
Barthel, S. R., Johansson, M. W., McNamee, D. M., & Mosher, D. F. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0607344 · Cited by 177
The collagen receptor subfamily of the integrins
White, D. J., Puranen, S., Johnson, M. S., & Heino, J. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.08.016 · Cited by 176
Loughman, A., Fitzgerald, J. R., Brennan, M. P., Higgins, J., Downer, R., Cox, D., & Foster, T. J. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04731.x · Cited by 176
Self-citationGadek, T. R., Burdick, D. J., McDowell, R. S., Stanley, M. S., Marsters, J. C., Paris, K. J., Oare, D. A., Reynolds, M. E., Ladner, C., Zioncheck, K. A., et al. (2002) · Science · doi:10.1126/science.295.5557.1086 · Cited by 172
Talin controls integrin activation
Calderwood, D. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320434 · Cited by 164
Ricart, A. D., Tolcher, A. W., Liu, G., Holen, K., Schwartz, G., Albertini, M., Weiss, G., Yazji, S., Ng, C., & Wilding, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0378 · Cited by 162
Lu, C., Takagi, J., & Springer, T. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100600200 · Cited by 162
α6 Integrin Is the Main Receptor of Human Papillomavirus Type 16 VLP
Yoon, C., Kim, K.-D., Park, S.-N., & Cheong, S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4838 · Cited by 161
Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins
Takagi, J. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320403 · Cited by 158
Graham, K. L., Halasz, P., Tan, Y., Hewish, M. J., Takada, Y., Mackow, E. R., Robinson, M. K., & Coulson, B. S. (2003) · Journal of Virology · doi:10.1128/jvi.77.18.9969-9978.2003 · Cited by 158
Transmembrane Domain Helix Packing Stabilizes Integrin αIIbβ3 in the Low Affinity State
Partridge, A. W., Liu, S., Kim, S., Bowie, J. U., & Ginsberg, M. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412701200 · Cited by 154
MacDonald, T. J., Stewart, C. F., Koçak, M., Goldman, S., Ellenbogen, R. G., Phillips∥, P. C., Lafond, D. A., Poussaint, T. Y., Kieran, M. W., Boyett, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1812 · Cited by 144
Scarborough, R. M. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70075-x · Cited by 143
Dubertret, L., Sterry, W., Bos, J. D., Chimenti, S., Shumack, S. P., Larsen, C. G., Shear, N. H., Papp, K. A., & CLEAR Multinational Study Group (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07344.x · Cited by 143
A structural basis for integrin activation by the cytoplasmic tail of the α IIb -subunit
Vinogradova, O., Haas, T., Plow, E. F., & Qin, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040548197 · Cited by 142
Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion
Kelly, T. A., Jeanfavre, D. D., McNeil, D. W., Woska, J. R., Reilly, P. L., Mainolfi, E. A., Kishimoto, K. M., Nabozny, G. H., X.-J.Zinter, R. W., Bormann, B., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5173 · Cited by 139
Murphy, M. G., Cerchio, K., Stoch, S. A., Gottesdiener, K. M., Wu, M., & Recker, R. R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2126 · Cited by 137
Shimaoka, M., Salas, A., Yang, W. Y., Weitz‐Schmidt, G., & Springer, T. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00238-3 · Cited by 134
The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin
Qu, A., & Leahy, D. J. (1996) · Structure · doi:10.1016/s0969-2126(96)00100-1 · Cited by 130
Petrich, B. G., Fogelstrand, P., Partridge, A. W., Yousefi, N., Ablooglu, A. J., Shattil, S. J., & Ginsberg, M. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31024 · Cited by 124
Jia, W., Li, H., & He, Y.-W. (2005) · Blood · doi:10.1182/blood-2005-04-1658 · Cited by 122
Integrin Subunit CD18 Is the T-Lymphocyte Receptor for the Helicobacter pylori Vacuolating Cytotoxin
Sewald, X., Gebert, B., Praßl, S., Barwig, I., Weiss, E., Fabbri, M., Osička, R., Schiemann, M., Busch, D. H., Semmrich, M., et al. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2007.11.003 · Cited by 122
Cox, D. M., Smith, R., Quinn, M. J., Théroux, P., Crean, P., & Fitzgerald, D. J. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00919-0 · Cited by 119
Self-citationWarnke, C., Menge, T., Hartung, H., Racke, M. K., Cravens, P. D., Bennett, J. L., Frohman, E. M., Greenberg, B. M., Zamvil, S. S., Gold, R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.161 · Cited by 118
An Essential Role for Talin during α M β 2 -mediated Phagocytosis
Lim, J., Wiedemann, A., Tzircotis, G., Monkley, S. J., Critchley, D. R., & Caron, E. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-09-0813 · Cited by 110
The Platelet Integrin αIIbβ3 Has an Endogenous Thiol Isomerase Activity
O'Neill, S., Robinson, A. A., Deering, A., Ryan, M., Fitzgerald, D. J., & Moran, N. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003279200 · Cited by 109
Self-citationFunahashi, Y., Sugi, N. H., Semba, T., Yamamoto, Y., Hamaoka, S., Tsukahara-Tamai, N., Ozawa, Y., Tsuruoka, A., Nara, K., Takahashi, K., et al. (2002) · PubMed · Cited by 103
Delbaldo, C., Raymond, É., Vera, K., Hammershaimb, L., Kaucic, K., Lozahic, S., Marty, M. E., & Faivre, S. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9077-0 · Cited by 101
Alpha-v Integrins as Therapeutic Targets in Oncology
Nemeth, J. A., Nakada, M. T., Trikha, M., Lang, Z., Gordon, M. S., Jayson, G. C., Corringham, R. E., Prabhakar, U., Davis, H. M., & Beckman, R. A. (2007) · Cancer Investigation · doi:10.1080/07357900701522638 · Cited by 100
α 5 β 1 -Integrin controls ebolavirus entry by regulating endosomal cathepsins
Schornberg, K. L., Shoemaker, C. J., Dube, D., Abshire, M. Y., Delos, S. E., Bouton, A. H., & White, J. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807578106 · Cited by 100
McDowall, A., Leitinger, B., Stanley, P., Bates, P. A., RANDI, A. M., & Hogg, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27396 · Cited by 99
Solution structures of the cytoplasmic tail complex from platelet integrin αIIb- and β3-subunits
Weljie, A. M., Hwang, P. M., & Vogel, H. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092515799 · Cited by 98
RTX cytotoxins recognize β 2 integrin receptors through N-linked oligosaccharides
Morová, J., Osička, R., Mašín, J., & Šebo, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711400105 · Cited by 97
Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring
Yang, W. Y., Shimaoka, M., Salas, A., Takagi, J., & Springer, T. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307340101 · Cited by 96
Defects in the Leukocyte Adhesion Cascade
Etzioni, A. (2009) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8132-3 · Cited by 95
Welzenbach, K., Hommel, U., & Weitz‐Schmidt, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110521200 · Cited by 82
Structure of the F‐spondin domain of mindin, an integrin ligand and pattern recognition molecule
Li, Y., Cao, C., Jia, W., Yu, L., Mo, M., Wang, Q., Huang, Y., Lim, J., Ishihara, M., Wells, L., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.288 · Cited by 79
A role for talin in presynaptic function
Morgan, J. R., Paolo, G. D., Werner, H. B., Shchedrina, V. A., Pypaert, M., Pieribone, V. A., & Camilli, P. V. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200406020 · Cited by 78
Moschos, S. J., Drogowski, L. M., Reppert, S. L., & Kirkwood, J. M. (2007) · PubMed · Cited by 77
Artoni, A., Li, J., Mitchell, B., Ruan, J., Takagi, J., Springer, T. A., French, D. L., & Coller, B. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404201101 · Cited by 77
Kalra, J., Warburton, C., Fang, K., Edwards, L., Daynard, T., Waterhouse, D., Dragowska, W. H., Sutherland, B. W., Dedhar, S., Gelmon, K. A., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2252 · Cited by 75
Integrin‐associated proteins as potential therapeutic targets
Cantor, J. M., Ginsberg, M. H., & Rose, D. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00640.x · Cited by 75
Integrin-linked kinase associated with integrin activation
Honda, S., Shirotani-Ikejima, H., Tadokoro, S., Maeda, Y., Kinoshita, T., Tomiyama, Y., & Miyata, T. (2009) · Blood · doi:10.1182/blood-2008-07-169136 · Cited by 70
Blue, R. C., Murcia, M., Karan, C., Jiroušková, M., & Coller, B. S. (2007) · Blood · doi:10.1182/blood-2007-08-105544 · Cited by 69
Regulation of Integrin αIIbβ3 Activation by Distinct Regions of Its Cytoplasmic Tails
Ma, Y., Yang, J., Pesho, M. M., Vinogradova, O., Qin, J., & Plow, E. F. (2006) · Biochemistry · doi:10.1021/bi060279h · Cited by 69
Analysis of Fyn function in hemostasis and αIIbβ3-integrin signaling
Reddy, K. B., Smith, D., & Plow, E. F. (2008) · Journal of Cell Science · doi:10.1242/jcs.014076 · Cited by 68
Manevich, E., Grabovsky, V., Feigelson, S. W., & Alon, R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700089200 · Cited by 67
Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives
Weitz‐Schmidt, G., Welzenbach, K., Dawson, J., & Kallen, J. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407951200 · Cited by 67
Oral GPIIb / IIIa Antagonists: What Went Wrong?
Cox, D. M. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384673 · Cited by 66
Self-citationComputationally Designed Peptide Inhibitors of Protein−Protein Interactions in Membranes
Caputo, G. A., Litvinov, R. I., Li, W., BENNETT, J. S., DeGrado, W. F., & Yin, H. H. (2008) · Biochemistry · doi:10.1021/bi800687h · Cited by 64
Antithrombotic effects of targeting αIIbβ3 signaling in platelets
Ablooglu, A. J., Kang, J., Petrich, B. G., Ginsberg, M. H., & Shattil, S. J. (2008) · Blood · doi:10.1182/blood-2008-09-180687 · Cited by 63
Liang, X., & Ji, Y. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.00917.x · Cited by 63
Human CD18 Is the Functional Receptor forAggregatibacter actinomycetemcomitansLeukotoxin
Dileepan, T., Kachlany, S. C., Balashova, N. V., Patel, J., & Maheswaran, S. K. (2007) · Infection and Immunity · doi:10.1128/iai.00314-07 · Cited by 62
Graham, K. L., Fleming, F. E., Halász, P., Hewish, M. J., Nagesha, H. S., Holmes, I. H., Takada, Y., & Coulson, B. S. (2005) · Journal of General Virology · doi:10.1099/vir.0.81102-0 · Cited by 61
Antithrombotics in Acute Coronary Syndromes
Bonaca, M. P., Steg, P. G., Feldman, L. J., Canales, J. F., Ferguson, J. J., Wallentin, L. C., Califf, R. M., Harrington, R. A., & Giugliano, R. P. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.083 · Cited by 60
Alpha4-integrin antagonism — an effective approach for the treatment of inflammatory diseases?
Davenport, R. J., & Munday, J. R. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.05.001 · Cited by 60
Furie, B. (2009) · Hematology · doi:10.1182/asheducation-2009.1.255 · Cited by 60
Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
Yao, K., Gagnon, S. J., Akhyani, N., Williams, E., Fotheringham, J., Frohman, E. M., Stüve, O., Monson, N. L., Racke, M. K., & Jacobson, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002028 · Cited by 59
Yuki, K., Astrof, N. S., Bracken, C., Yoo, R., Silkworth, W., Soriano, S. G., & Shimaoka, M. (2008) · The FASEB Journal · doi:10.1096/fj.08-113324 · Cited by 53
Protein Phosphatase 1 Associates with the Integrin αIIb Subunit and Regulates Signaling
Vijayan, K. V., Liu, Y., Li, T.-T., & Bray, P. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400239200 · Cited by 52
Therapeutic anti‐integrin (α4 and αL) monoclonal antibodies: two‐edged swords?
González‐Amaro, R., Mittelbrunn, M., & Sánchez‐Madrid, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02225.x · Cited by 51
Potin, D., Launay, M., Monatlik, F., Malabre, P., Fabreguettes, M., Fouquet, A., Maillet, M., Nicolaï, E., Dorgeret, L., Chevallier, F., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0610806 · Cited by 51
Structural basis of integrin transmembrane activation
Wang, W., & Luo, B. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22427 · Cited by 50
Shimaoka, M., Kim, M., Cohen, E. H., Yang, W. Y., Astrof, N. S., Peer, D., Salas, A., Ferrand, A., & Springer, T. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605716103 · Cited by 50
1,4-Diazepane-2-ones as novel inhibitors of LFA-1
Wattanasin, S., Albert, R., Ehrhardt, C., Roche, D., Sabio, M. L., Hommel, U., Welzenbach, K., & Weitz‐Schmidt, G. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00991-5 · Cited by 50
Efalizumab binding to the LFA-1 α L I domain blocks ICAM-1 binding via steric hindrance
Li, S., Wang, H., Peng, B., Zhang, M., Zhang, D., Hou, S., Guo, Y., & Ding, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810844106 · Cited by 49
Rosenthal, M. A., DAVIDSON, P., Rolland, F., Campone, M., Xue, L., Han, T. H., MEHTA, A., Berd, Y., He, W., & Lombardi, A. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2009.01266.x · Cited by 48
Keating, S. M., Clark, K., Stefanich, L. D., et al. (2005) · Protein Science · doi:10.1110/ps.051583406 · Cited by 46
Laurens, N., Engelse, M. A., Jungerius, C., Löwik, C. W. G. M., van Hinsbergh, V. W. M., & Koolwijk, P. (2009) · Angiogenesis · doi:10.1007/s10456-009-9150-8 · Cited by 44
Watterson, S. H., Xiao, Z., Dodd, D. S., Tortolani, D. R., Vaccaro, W. D., Potin, D., Launay, M., Stetsko, D. K., Skala, S., Davis, P. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100348u · Cited by 43
Integrin-associated Lyn Kinase Promotes Cell Survival by Suppressing Acid Sphingomyelinase Activity
Chudakova, D. A., Zeidan, Y. H., Wheeler, B. W., Yu, J., Novgorodov, S. A., Kindy, M. S., Hannun, Y. A., & Gudz, T. I. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803301200 · Cited by 43
Zhang, H., Astrof, N. S., Liu, J., Wang, J., & Shimaoka, M. (2009) · The FASEB Journal · doi:10.1096/fj.09-129908 · Cited by 41
Kato, A., Kawamata, N., Tamayose, K., Egashira, M., Miura, R., Fujimura, T., Murayama, K., & Oshimi, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204340200 · Cited by 38
Dassanayake, R. P., Maheswaran, S. K., & Srikumaran, S. (2007) · Infection and Immunity · doi:10.1128/iai.00808-07 · Cited by 37
New approaches to blockade of α4-integrins, proven therapeutic targets in chronic inflammation
Kummer, C., & Ginsberg, M. H. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.014 · Cited by 35
Muranyi, A., Dedhar, S., & Hogge, D. E. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.01.002 · Cited by 34
Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5
Sroka, T. C. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl005 · Cited by 34
Protein Phosphatase 2A Negatively Regulates Integrin αIIbβ3 Signaling
Gushiken, F. C., Patel, V., Liu, Y., Pradhan, S., Bergeron, A. L., Peng, Y., & Vijayan, K. V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708804200 · Cited by 33
RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin αIIbβ3
Brophy, T. M., Raab, M., Daxecker, H., Culligan, K., Lehmann, I. T., Chubb, A. J., Treumann, A., & Moran, N. M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.142 · Cited by 33
Self-citationThe Cytosolic Protein Talin Induces an Intermediate Affinity Integrin αLβ2
Li, Y.-F., Tang, R.-H., Puan, K.-J., Law, S. K. A., & Tan, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701860200 · Cited by 32
Ng, C. M., Bai, S., Takimoto, C. H. M., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1023-8 · Cited by 31
Hyduk, S. J., Oh, J., Xiao, H., Chen, M., & Cybulsky, M. I. (2004) · Blood · doi:10.1182/blood-2003-12-4402 · Cited by 28
Kummer, C., Petrich, B. G., Rose, D. M., & Ginsberg, M. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066993 · Cited by 27
Lee, H., Kim, S., Koh, J., Bok, J., Kim, K.-J., Kim, K.-S., Park, M., Shin, H.-D., Park, B. L., Kim, T., et al. (2007) · Bone · doi:10.1016/j.bone.2007.08.034 · Cited by 27
Bennett, J. L. (2006) · Neurological Research · doi:10.1179/016164106x98189 · Cited by 25
Very late antigen-4 integrin antagonists
Tilley, J. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.841 · Cited by 24
Rotavirus-neutralizing antibodies inhibit virus binding to integrins α2β1 and α4β1
Fleming, F. E., Graham, K. L., Taniguchi, K., Takada, Y., & Coulson, B. S. (2007) · Archives of Virology · doi:10.1007/s00705-007-0937-x · Cited by 23
Xemilofiban/Orbofiban: Insight into Drug Development
Anders, R. J., Kleiman, J. H., Nicholson, N. S., Wazowicz, B., & Burns, D. M. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00059.x · Cited by 22
Aylward, K., Meade, G., Ahrens, I., Devocelle, M. C., & Moran, N. M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02041.x · Cited by 19
Self-citationAhrens, I., & Peter, K. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-03-0194 · Cited by 10
UR-3216: A New Generation Oral Platelet GPIIb / IIIa Antagonist
Aga, Y., Baba, K., Tam, S. H., Nakanishi, T., Yoneda, K., Kita, J., & Ueno, H. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384592 · Cited by 10
Ligand Switching in Cell-Permeable Peptides: Manipulation of the α-Integrin Signature Motif
Bernard, E., Parthasarathi, L., Cho, M., Aylward, K., Raab, M., Daxecker, H., O’Dushlaine, C. T., Shields, D. C., Devocelle, M. C., Keyes, T. E., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb8002623 · Cited by 9
Self-citationBlocking α4-integrins — A small molecule approach to treatment of multiple sclerosis
Davenport, R. J., & Munday, J. R. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.05.025 · Cited by 7
Cited by
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
Mas-Moruno, C., Rechenmacher, F., & Kessler, H. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728639 · Cited by 647
Kapp, T. G., Rechenmacher, F., Neubauer, S., Maltsev, O. V., Cavalcanti-Adam, E. A., Zarka, R., Reuning, U., Notni, J., Wester, H.-J., Mas-Moruno, C., et al. (2017) · Scientific Reports · doi:10.1038/srep39805 · Cited by 620
Metadata
- Authors
- Cox, D., Brennan, M., & Moran, N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-10
- Volume
- 9
- Issue
- 10
- Pages
- 804-820
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1966022051
- Cited by
- 456
- References
- 167
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.